Ladenburg raised the firm’s price target on Corvus Pharmaceuticals to $21 from $12 and keeps a Buy rating on the shares. The firm expanded its model for soquelitinib to include atopic dermatitis, in addition to the current focus on peripheral T-cell lymphoma and solid tumors, as Corvus anticipates Phase 1 atopic dermatitis randomized data by year-end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Biotech Alert: Searches spiking for these stocks today
- Corvus Pharmaceuticals initiates registrational Phase 3 trial of soquelitinib
- Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
- Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Corvus Pharmaceuticals files $200M mixed securities shelf
